312 related articles for article (PubMed ID: 22644716)
21. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Marshall JK; Thabane M; Steinhart AH; Newman JR; Anand A; Irvine EJ
Cochrane Database Syst Rev; 2010 Jan; (1):CD004115. PubMed ID: 20091560
[TBL] [Abstract][Full Text] [Related]
22. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
Ardizzone S; Doldo P; Ranzi T; Sturniolo GC; Giglio LA; Annese V; D'Arienzo A; Gaia E; Gullini S; Riegler G; Valentini M; Massa P; Del Piano M; Rossini F; Guidetti CS; Pera A; Greinwald R; Bianchi Porro G
Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):677-84. PubMed ID: 10730559
[TBL] [Abstract][Full Text] [Related]
23. Release of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH Levels.
Abinusawa A; Tenjarla S
Adv Ther; 2015 May; 32(5):477-84. PubMed ID: 25951927
[TBL] [Abstract][Full Text] [Related]
24. Colonic spread of three rectally administered mesalazine (Pentasa) dosage forms in healthy volunteers as assessed by gamma scintigraphy.
Brown J; Haines S; Wilding IR
Aliment Pharmacol Ther; 1997 Aug; 11(4):685-91. PubMed ID: 9305476
[TBL] [Abstract][Full Text] [Related]
25. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis.
Safdi M; DeMicco M; Sninsky C; Banks P; Wruble L; Deren J; Koval G; Nichols T; Targan S; Fleishman C; Wiita B
Am J Gastroenterol; 1997 Oct; 92(10):1867-71. PubMed ID: 9382054
[TBL] [Abstract][Full Text] [Related]
26. Does the 5-Aminosalicylate Concentration Correlate with the Efficacy of Oral 5-Aminosalicylate and Predict Response in Patients with Inflammatory Bowel Disease? A Systematic Review.
van de Meeberg MM; Schultheiss JPD; Oldenburg B; Fidder HH; Huitema ADR
Digestion; 2020; 101(3):245-261. PubMed ID: 31013494
[TBL] [Abstract][Full Text] [Related]
27. Drug therapy for ulcerative colitis.
Xu CT; Meng SY; Pan BR
World J Gastroenterol; 2004 Aug; 10(16):2311-7. PubMed ID: 15285010
[TBL] [Abstract][Full Text] [Related]
28. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis.
Marshall JK; Irvine EJ
Am J Gastroenterol; 2000 Jul; 95(7):1628-36. PubMed ID: 10925961
[TBL] [Abstract][Full Text] [Related]
29. Ulcerative proctitis: a review of pharmacotherapy and management.
Lakatos PL; Lakatos L
Expert Opin Pharmacother; 2008 Apr; 9(5):741-9. PubMed ID: 18345952
[TBL] [Abstract][Full Text] [Related]
30. Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study.
Nagahori M; Kochi S; Hanai H; Yamamoto T; Nakamura S; Omuro S; Watanabe M; Hibi T;
BMC Gastroenterol; 2017 Apr; 17(1):47. PubMed ID: 28390410
[TBL] [Abstract][Full Text] [Related]
31. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
Sandborn WJ; Regula J; Feagan BG; Belousova E; Jojic N; Lukas M; Yacyshyn B; Krzeski P; Yeh CH; Messer CA; Hanauer SB
Gastroenterology; 2009 Dec; 137(6):1934-43.e1-3. PubMed ID: 19766640
[TBL] [Abstract][Full Text] [Related]
32. Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study.
Richter JM; Kushkuley S; Barrett JA; Oster G
Aliment Pharmacol Ther; 2012 Aug; 36(3):248-56. PubMed ID: 22690748
[TBL] [Abstract][Full Text] [Related]
33. Topical therapy is underused in patients with ulcerative colitis.
Seibold F; Fournier N; Beglinger C; Mottet C; Pittet V; Rogler G;
J Crohns Colitis; 2014 Jan; 8(1):56-63. PubMed ID: 23566922
[TBL] [Abstract][Full Text] [Related]
34. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations?
Sandborn WJ
J Clin Gastroenterol; 2008 Apr; 42(4):338-44. PubMed ID: 18277908
[TBL] [Abstract][Full Text] [Related]
35. Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamine.
Deng X; Tolstanova G; Khomenko T; Chen L; Tarnawski A; Szabo S; Sandor Z
J Pharmacol Exp Ther; 2009 Dec; 331(3):1071-8. PubMed ID: 19762547
[TBL] [Abstract][Full Text] [Related]
36. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
Christensen LA
Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
[TBL] [Abstract][Full Text] [Related]
37. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
[TBL] [Abstract][Full Text] [Related]
38. The role of aminosalicylates in the treatment of ulcerative colitis.
Van Assche G; Baert F; De Reuck M; De Vos M; De Wit O; Hoang P; Louis E; Mana F; Pelckmans P; Rutgeerts P; Van Gossum A; D'Haens G
Acta Gastroenterol Belg; 2002; 65(4):196-9. PubMed ID: 12619425
[TBL] [Abstract][Full Text] [Related]
39. Tailoring the mucoadhesive and sustained release characteristics of mesalamine loaded formulations for local treatment of distal forms of ulcerative colitis.
Ali HS; Hanafy AF; El Achy SN
Eur J Pharm Sci; 2016 Oct; 93():233-43. PubMed ID: 27503459
[TBL] [Abstract][Full Text] [Related]
40. Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis.
Piodi LP; Ulivieri FM; Cermesoni L; Cesana BM
Scand J Gastroenterol; 2004 Feb; 39(2):154-7. PubMed ID: 15000277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
